A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Trial details
- Registry ID
- NCT06335173
- Drugs studied
- sabirnetug
TrialRedline tracks 1 clinical trial sponsored by Acumen Pharmaceuticals: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 | sabirnetug | Active not recruiting | 2026-10-29Actual |
Names as written in the registry records.
NCT06335173 · Acumen Pharmaceuticals
Before: Estimated. After: Actual.
Before: Oct 2026. After: 29 Oct 2026.